Jose Lujan-Palma, MD
Neurology · Roswell, NMNPI 1407880867
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,528 of the $3,989 with a category attached, or 63.4%. 25 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 37.2% of the total. Reporting peaked in 2019 at $1,754 and has fallen 84.9% since, to $265 in 2025.
Across 102 payments — averaging $39.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Medtronic$1K
- UCB, Inc.$235
- AbbVie$224
- Amgen$212
- Novartis$107
- plus $711 from 19 others
What the payments were for
- Travel & lodging$1,36134%
- Food & beverage$2,52863%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $1,485 |
| Medtronic(2 entities) | 13 | $1,015 |
| UCB, Inc. | 15 | $235 |
| AbbVie | 12 | $224 |
| Amgen(2 entities) | 7 | $212 |
| Novartis | 6 | $107 |
| Genentech USA, Inc. | 6 | $97 |
| Pfizer | 5 | $74 |
| Neurelis, Inc. | 3 | $65 |
| Argenx US, Inc. | 3 | $65 |
| Lilly USA, LLC | 3 | $58 |
| Neurocrine Biosciences, Inc. | 3 | $55 |
| EMD Serono, Inc. | 3 | $48 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Lundbeck LLC | 1 | $29 |
| AstraZeneca | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Tanabe Pharma America, Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| CSL Behring | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Biogen | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,989 in reported general payments places this provider in the 75th percentile of 91 neurology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 12 | $68,861 |
| Rufinamide | 33 | $59,478 |
| KeppraLevetiracetam | 16 | $49,320 |
| EpidiolexCannabidiol (Cbd) | 11 | $43,687 |
| Clobazam | 98 | $16,776 |
| Oxcarbazepine | 64 | $15,513 |
| Emgality PenGalcanezumab-Gnlm | 18 | $14,755 |
| VimpatLacosamide | 11 | $13,291 |
| Lacosamide | 84 | $12,209 |
| Levetiracetam | 187 | $10,985 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,141 |
| Carbamazepine ErCarbamazepine | 33 | $6,923 |
| Tegretol XrCarbamazepine | 11 | $6,728 |
| Memantine Hcl | 123 | $4,577 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 196 | $4,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $1,485 | $68,86112 claims |
| UCB, Inc.Vimpat | $235 | $13,29111 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $31 | $3,35134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 91 neurology providers in New Mexico.
Other neurology in Roswell
- Heba SamaraRoswell$927
- Elaine EdmondsAlbuquerque$610K
- Kader AbdelerahmanAlbuquerque$607K
- Weiwei DaiRio Rancho$367K
- Timothy OwnbeyAlbuquerque$90K
- Gerson Suarez CedenoAlbuquerque$44K
- Corey FordAlbuquerque$27K
- Diksha MohantyAlbuquerque$20K
- Douglas BarrettAlbuquerque$19K
- Vanessa Licona SanjuanAlbuquerque$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.